SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin surges on the buzz of hiking price of its generic diabetes drug Fortamet

24 Sep 2015 Evaluate

Lupin is currently trading at Rs. 1983.80, up by 62.50 points or 3.25% from its previous closing of Rs. 1921.30 on the BSE.

The scrip opened at Rs. 1946.00 and has touched a high and low of Rs. 2002.00 and Rs. 1946.00 respectively. So far 47089 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2112.00 on 08-Apr-2015 and a 52 week low of Rs. 1307.10 on 16-Oct-2014.

Last one week high and low of the scrip stood at Rs. 2002.00 and Rs. 1841.10 respectively. The current market cap of the company is Rs. 89372.77 crore.

The promoters holding in the company stood at 46.59% while Institutions and Non-Institutions held 43.57% and 9.84% respectively.

Lupin has reportedly hiked price of its generic diabetes drug Fortamet by three times for 500 mg and 1000 mg variants. Despite the price hike, the company’s drug is still 15% cheaper than its innovator.

Fortamet has two generic players in the market, Lupin and Mylan. Lupin has 60% market share of the drug in value terms. Mylan, which got the approval for the drug in 2013, has not yet launched its generic version. Fortamet’s current market size is estimated at $170 million.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations as well as biotechnology products and APIs globally.

 

Lupin Share Price

2395.25 -24.90 (-1.03%)
01-Jul-2026 11:11 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1872.95
Dr. Reddys Labs. 1342.20
Cipla 1453.50
Zydus Lifesciences 1110.50
Lupin 2395.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: